Log in

Relevant bibliographies by topics / National Heart and Lung Institute

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'National Heart and Lung Institute'

Author: Grafiati

Published: 4 June 2021

Last updated: 18 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'National Heart and Lung Institute.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "National Heart and Lung Institute"

1

Nabel, Elizabeth G. "National Heart, Lung, and Blood Institute." Circulation 119, no. 10 (2009): 1453–55. http://dx.doi.org/10.1161/circulationaha.108.841551.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Robbins, Ivan M., Timothy M. Moore, Carol J. Blaisdell, and Steven H. Abman. "National Heart, Lung, and Blood Institute Workshop." Circulation 125, no. 17 (2012): 2165–70. http://dx.doi.org/10.1161/circulationaha.112.092924.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

&NA;. "National Heart and Lung Institute Course in Lung Pathology." American Journal of Surgical Pathology 13, no. 3 (1989): 249. http://dx.doi.org/10.1097/00000478-198903000-00015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Burns, Kristin M. "Paediatric heart failure research: role of the National Heart, Lung, and Blood Institute." Cardiology in the Young 25, S2 (2015): 167–71. http://dx.doi.org/10.1017/s1047951115000979.

Full text

Abstract:

AbstractThe National Heart, Lung, and Blood Institute, of the National Institutes of Health, is committed to supporting research in paediatric heart failure. The Institute’s support of paediatric heart failure research includes both investigator-initiated grants and Institute initiatives. There were 107 funded grants in paediatric heart failure over the past 20 years in basic, translational and clinical research, technology development, and support of registries. Such research includes a broad diversity of scientific topics and approaches. The Institute also supports several initiatives for paediatric heart failure, including the Pediatric Circulatory Support Program, the Pumps for Kids, Infants, and Neonates (PumpKIN) Program, PediMACS, and the Pediatric Heart Network. This review article describes the National Heart, Lung, and Blood Institute’s past, present, and future efforts to promote a better understanding of paediatric heart failure, with the ultimate goal of improving outcomes.

APA, Harvard, Vancouver, ISO, and other styles

5

&NA;. "Forthcoming Meetings at National Heart & Lung Institute, London." American Journal of Surgical Pathology 16, no. 1 (1992): 94. http://dx.doi.org/10.1097/00000478-199201000-00022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Lenfant, Claude, and David R. Harder. "News from the National Heart, Lung, and Blood Institute." American Journal of Physiology-Heart and Circulatory Physiology 277, no. 3 (1999): H855—H856. http://dx.doi.org/10.1152/ajpheart.1999.277.3.h855.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Lauer, Michael S., James P. Kiley, Stephen C. Mockrin, et al. "National Heart, Lung, and Blood Institute (NHLBI) Strategic Visioning." Circulation 131, no. 12 (2015): 1106–9. http://dx.doi.org/10.1161/circulationaha.115.015712.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Dilling, Daniel. "The National Heart, Lung, and Blood Institute Lymphangioleiomyomatosis Registry." Chest 155, no. 2 (2019): 249–50. http://dx.doi.org/10.1016/j.chest.2018.09.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Lenfant, Claude. "National Heart, Lung, and Blood Institute Cardiothoracic Surgery Program." Circulation 102, no. 11 (2000): 1212–13. http://dx.doi.org/10.1161/01.cir.102.11.1212.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Hurd, S. S., and C. Lenfant. "The National Heart, Lung and Blood Institute asthma program." Chest 101, no. 6 (1992): 359S—361. http://dx.doi.org/10.1378/chest.101.6.359s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "National Heart and Lung Institute"

1

Cooper, Heather L. "Evidence-based practice and asthma guideline adherence and barriers a study of a university family practice clinic /." Laramie, Wyo. : University of Wyoming, 2007. http://proquest.umi.com/pqdweb?did=1400966251&sid=1&Fmt=2&clientId=18949&RQT=309&VName=PQD.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Smith, Linda M. "Educational Intervention: Effects on Heart Disease Risk Factor Knowledge Among African Americans." ScholarWorks, 2015. https://scholarworks.waldenu.edu/dissertations/1627.

Full text

Abstract:

Abstract Fatal coronary heart disease among African Americans is associated with a disproportionate burden of cardiovascular disease (CVD) risk factors. Research has indicated that CVD risk factor knowledge and the prevalence of ideal CVH both persist at suboptimal levels. However, few researchers have investigated the relationship between culturally-tailored community-based heart health sessions, short-term knowledge acquisition of CVD risk factors, and the awareness of the American Heart Association's (AHA's) CVH construct. The purpose of this cross-sectional, secondary analysis study was to examine the interplay between these variables in an urban African American sample. Guided by social cognitive theory, the study analyzed de-identified data (data sets of demographic characteristics and Heart Disease Facts Questionnaire) from participant responses collected at multiple community sites to assist in the planning of future health programs. Multiple community sites were randomized into an intervention (n = 50) or comparison group (n = 57). Pearson's correlation and multiple regression were used to analyze data. Knowledge was higher for intervention group participants (Î² =.44, p = .001) and tended to be higher for those with more education (Î² = .20, p = .06) and those with less income (Î² = -.22, p = .07). Notably, most participants (73%) reported awareness of the AHA construct, CVH. The results support culturally-tailored interventions as a useful strategy for CVD risk reduction. The implication for social change is that initiatives at the community-level may positively impact CVH in minority/ethnic communities and subsequently impact CVD disparities.

APA, Harvard, Vancouver, ISO, and other styles

3

Navaratnam, Prakash. "Predictors of the prescribing of asthma pharmacotherapy in the ambulatory patient population of the United States." Columbus, Ohio : Ohio State University, 2007. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1171582748.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

McIntosh, Anna M. G. "The relationship of the Diet Quality Index to prevalence of overweight in black and white adolescent girls : an examination of data from the National Heart, Lung, and Blood Institute's Growth and Health Study /." Thesis, This resource online, 1995. http://scholar.lib.vt.edu/theses/available/etd-01312009-063137/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Lai, Lana Yin Hui. "Association of Apolipoprotein E (Apo E) polymorphism with the prevalence of metabolic syndrome (MetS): the National Heart, Lung and Blood Institute Family Heart Study." Thesis, 2013. https://hdl.handle.net/2144/17153.

Full text

Abstract:

BACKGROUND & AIMS - Metabolic syndrome (MetS), characterized by abdominal obesity, atherogenic dyslipidemia, elevated blood pressure, and insulin resistance is a major public health concern in the United States. The effect of Apolipoprotein E (Apo E) polymorphism has been relatively well studied in relation to cardiovascular disease; however, its effects on MetS are not well established. METHODS - We conducted a cross-sectional study consisting of 1,551 participants from the National Heart, Lung, and Blood Institute (NHLBI) Family Heart Study to assess the relation of Apo E polymorphism with the prevalence of MetS. Information on the different Apo E genotypes was extracted from the database and we defined MetS according to the AHA-NHLBI-IDF-WHO Harmonized Criteria. We used generalized estimating equations to estimate adjusted odds ratios for prevalent MetS and the Bonferroni correction to account for multiple testing in the secondary analysis. RESULTS – Our study population had a mean age (SD) of 56.5 (11.0) years and 49.7% had MetS. There was no association between the Apo E genotypes and MetS. The multivariable adjusted ORs (95% CI) were 1.00 (reference), 1.26 (0.31-5.21), 0.89 (0.62- 1.29), 1.13 (0.61-2.10), 1.13 (0.88-1.47) and 1.87 (0.91-3.85) for the *e3/e3, *e2/e2, *e2/e3, *e2/e4, *e3/e4 and *e4/e4 genotype respectively. In a secondary analysis, the *e2/e3 genotype was associated with lower HDL levels, with the multivariable adjusted ORs (95% CI) of 0.59 (0.36-0.95) when compared to the reference *e3/e3 genotype. CONCLUSIONS - Our findings do not support an association between Apo E polymorphism and MetS in a multi-center population based study of predominantly white US men and women. The *e2/e3 genotype was associated with lower HDL levels as compared to the *e3/e3 genotype. KEY WORDS: Apolipoprotein E (Apo E) polymorphism, metabolic syndrome, blood pressure, glucose, waist circumference, triglycerides, high-density lipoprotein cholesterol

APA, Harvard, Vancouver, ISO, and other styles

6

TSUI, Yu-Wen, and 崔愉雯. "Research on the relationship between Ischemic Heart Disease and Lung Cancer Based on Taiwan National Healthcare Insurance Database." Thesis, 2016. http://ndltd.ncl.edu.tw/handle/35020462621903356824.

Full text

Abstract:

碩士
亞洲大學
生物資訊與醫學工程學系碩士在職專班
104
Ischemic Heart Disease is a common disease in Taiwan, and lung cancer has become “Taiwan National Disease” with it rapidly death rate. Both diseases have the same genetic structure, and no one has done the research on the relationship between those two, therefore this is what this report is going to focus on. First, the report uses 1,307- Ischemic Heart Disease patients’ samples from 2006 to 2010, then cross analysis with the 48,479 lung cancer patients’ sample within the same period of time. Using Independent t Test, Chi-square Test and Cox Model, does the analysis. The research shows Ischemic Heart Disease and Lung Cancer share some genetic structures therefore we can speculate the connection between those two diseases. Then results highlight that males have higher chance to have Ischemic Heart Disease, and so do the older people. Another significant result shows, people who have underlying cause of lung cancer (Tuberculosis, Pneumonia, Emphysema, Chronic Bronchitis, Silicosis) tend to have higher chance to have Ischemic Heart Disease. Furthermore, the report finds that Ischemic Heart Disease patients have lower economic level compare to people who don’t. Lastly, We adjust HR standard to 0.94 (95% Confident Integrate: 0.50 ~1.77), and it demonstrate Ischemic Heart Disease does not cause cancers.

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "National Heart and Lung Institute"

1

J, Culliton Barbara, ed. Vital signs: Discoveries in diseases of the heart, lungs and blood. Medical Communications Resources, Inc., 1998.

APA, Harvard, Vancouver, ISO, and other styles

2

R, Hogness John, VanAntwerp Malin, and National Heart, Lung, and Blood Institute., eds. The artificial heart: Prototypes, policies, and patients. National Academy Press, 1991.

APA, Harvard, Vancouver, ISO, and other styles

3

National Heart, Lung, and Blood Institute. Research training & career development programs of the National Heart, Lung, and Blood Institute. National Institutes of Health, Dept. of Health and Human Services, Public Health Service, 1993.

APA, Harvard, Vancouver, ISO, and other styles

4

Research training & career development programs of the National Heart, Lung, and Blood Institute. National Institutes of Health, Dept. of Health and Human Services, Public Health Service, 1993.

APA, Harvard, Vancouver, ISO, and other styles

5

National Heart, Lung, and Blood Institute. Research training & career development programs of the National Heart, Lung, and Blood Institute. National Institutes of Health, Dept. of Health and Human Services, Public Health Service, 1993.

APA, Harvard, Vancouver, ISO, and other styles

6

National Heart, Lung, and Blood Institute. Office of Prevention, Education, and Control. Educational materials catalog. U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, Office of Prevention, Education, and Control, 2001.

APA, Harvard, Vancouver, ISO, and other styles

7

National Heart, Lung, and Blood Institute. Educational materials catalog. U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, 1994.

APA, Harvard, Vancouver, ISO, and other styles

8

National Heart, Lung, and Blood Institute. Office of Prevention, Education, and Control. Educational materials catalog. U.S. Dept. of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, Office of Prevention, Education, and Control, 2004.

APA, Harvard, Vancouver, ISO, and other styles

9

National Heart, Lung, and Blood Institute. Office of Prevention, Education, and Control. Educational materials catalog. U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, Office of Prevention, Education, and Control, 1997.

APA, Harvard, Vancouver, ISO, and other styles

10

L, Caron Marc, National Heart, Lung, and Blood Institute, and American Heart Association, eds. Receptors and cell activation: A summary of the Frontiers in Basic Sciences That Relate to Heart, Lung, and Blood Diseases Symposium : National Heart, Lung, and Blood Institute : administrative report. The Institute, 1987.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "National Heart and Lung Institute"

1

Tiro, Jasmin, Simon J. Craddock Lee, Steven E. Lipshultz, et al. "National Heart, Lung, and Blood Institute." In Encyclopedia of Behavioral Medicine. Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4419-1005-9_817.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Hall, Martica H. "National Heart, Lung, and Blood Institute." In Encyclopedia of Behavioral Medicine. Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-39903-0_817.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Frommer, Peter L. "An overview of the National Heart, Lung, and Blood Institute Artificial Heart Program." In Artificial Heart 3. Springer Japan, 1991. http://dx.doi.org/10.1007/978-4-431-68126-7_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Ohar, Jill, and Eugene R. Bleecker. "National Heart, Lung, and Blood Institute Guidelines: Treatment of Asthma." In Current Review of Asthma. Current Medicine Group, 2003. http://dx.doi.org/10.1007/978-1-4613-1095-2_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Silverman, Mark E., and Aubrey Leatham. "Part II · The Institute of Cardiology and the National Heart and Lung Institute." In British Cardiology in the 20th Century. Springer London, 2000. http://dx.doi.org/10.1007/978-1-4471-0773-6_7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Boushey, Homer A., and Rajeev Venkayya. "National Heart, Lung, and Blood Institute Guidelines: Classification of Asthma Severity." In Current Review of Asthma. Current Medicine Group, 2003. http://dx.doi.org/10.1007/978-1-4613-1095-2_13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Mondoro, Traci Heath, and John Thomas. "National Heart, Lung, and Blood Institute Support of Cellular Therapies Regenerative Medicine." In Mesenchymal Stromal Cells. Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-5711-4_22.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ginsberg, Henry N. "New Directions in Dietary Studies and Heart Disease: The National Heart, Lung and Blood Institute Sponsored Multicenter Study of Diet Effects on Lipoproteins and Thrombogenic Activity." In Nutrition and Biotechnology in Heart Disease and Cancer. Springer US, 1995. http://dx.doi.org/10.1007/978-1-4615-1957-7_23.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Greenwald, Peter, Carolyn Clifford, Susan Pilch, Jerianne Heimendinger, and Gary Kelloff. "New Directions in Dietary Studies in Cancer: The National Cancer Institute." In Nutrition and Biotechnology in Heart Disease and Cancer. Springer US, 1995. http://dx.doi.org/10.1007/978-1-4615-1957-7_22.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Aziz, Kalimuddin. "Prevalence of Heart Disease in Children at the National Institute of Cardiovascular Disease in Pakistan." In Pediatric Cardiology. Springer New York, 1986. http://dx.doi.org/10.1007/978-1-4613-8598-1_309.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "National Heart and Lung Institute"

1

Burkart, Kristin M., Melinda Aldrich, Jemma Wilk, et al. "Genome-Wide Association Study (GWAS) Of Lung Function Among African-Americans In 5 National Heart, Lung, And Blood Institute (NHLBI) Cohorts. The Candidate-Gene Association Resource (CARE)." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1752.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Roszelle, Breigh N., Steven Deutsch, and Keefe B. Manning. "A Comprehensive Flow Study of the 12 cc Penn State Pulsatile Pediatric Ventricular Assist Device." In ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-192743.

Full text

Abstract:

While medical options for children born with congenital heart defects include transplantation, the amount of available organs remains limited. This lack of donors led to the development of the National Institute of Health’s National Heart, Lung and Blood Institute Pediatric Circulatory Support Program. Contracts have been awarded to five teams with the task of creating novel support systems for children, ranging from 2 to 25 kg [1]. As part of this program, Penn State has developed a 12 cc pulsatile pediatric ventricular assist device (PVAD), based on the successful 70 cc Pierce-Donachy adult assist device. During the process of reducing the volume of the device for pediatric use, changes were made to the design including altering the angles of the inlet and outlet ports. Previous two-dimensional flow visualization in the PVAD by Manning et al. had shown that these changes led to an increased three-dimensionality of the flow, the influence of which required further investigation [2]. It is important to characterize the fluid dynamics of the flow field inside assist devices such as the PVAD because certain characteristics including high blood residence time, stagnant flow and wall shear rates below 500 s−1 can lead to an increased propensity of thrombus deposition [3,4].

APA, Harvard, Vancouver, ISO, and other styles

3

Petraiuolo, W., E. Bovill, and J. Hoak. "THE LUPUS ANTICOAGULANT DOES NOT INHIBIT THE RELEASE OF PROSTACYCLIN FROM HUMAN ENDOTHELIAL CELLS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644228.

Full text

Abstract:

Decreased endothelial cell production of prostacyclin (PGI2) in response to the lupus anticoagulant has been previously demonstrated, and postulated to have a causal relationship to the thrombotic events associated with the lupus anticoagulant. Five patients who exhibited the anticoagulant were studied in an effort to determine if a relationship exists between exposure of endothelial cells to the lupus anticoagulant and decreased production of prostacyclin (PGI2). Human endothelial cells derived from human umbilical vein grown in culture were exposed to IgG fractions of patient plasmas containing the lupus anticoagulant. The amount of PGI2 released was determined by radioimmunoassay for 6-keto-PGF-l-alpha. The average PGI2 release in the controls was 20.6 picomol/500,000 endothelial cells, whereas those cells exposed to the lupus anticoagulant had a range of 25 to 114 picmol/500,000 cells. We were unable to demonstrate inhibition of the release of PGI2 by human endothelial cells, following exposure to the lupus anticoagulant.(Supported by NIH Grant HL 33723-2 and a Specialized Center of Research in Thrombosis Award HL 35058-01 from the National Heart, Lung and Blood Institute.)

APA, Harvard, Vancouver, ISO, and other styles

4

Colebeck, E., M. Asili, R. Green, and E. Topsakal. "The effect of temperature on the microwave dielectric properties of porcine liver, lung, and heart." In 2013 US National Committee of URSI National Radio Science Meeting (USNC-URSI NRSM). IEEE, 2013. http://dx.doi.org/10.1109/usnc-ursi-nrsm.2013.6525131.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kinsella, C., SA Thorne, PF Clift, et al. "30 Managing delivery in women with congenital heart disease: results from the cuban national programme for pregnancy and heart disease." In British Congenital Cardiac Association, Annual meeting abstracts 9–10 November 2017, Great Ormond Street Institute of Child Health, London, UK. BMJ Publishing Group Ltd and British Cardiovascular Society, 2018. http://dx.doi.org/10.1136/heartjnl-2017-bcca.30.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Prakash, Arvind, Rachita Dhawan, Anirban Kundu, Vikas Ahalawhat, and Om Yadava. "A Rare Case of Coronary Cameral Fistula with Patent Ductus Arteriosus, National Heart Institute, New Delhi." In 5th annual conference of SWAC ELSO. Thieme Medical and Scientific Publishers Private Ltd., 2017. http://dx.doi.org/10.1055/s-0038-1639416.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Roberts, H. R. "PREVENTION OF DEEP VENOUS THROMBOSIS: CONCLUSIONS OF A CONSENSUS DEVELOPMENT CONFERENCE." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642966.

Full text

Abstract:

Deep venous thrombosis (DVT) and pulmonary embolism (PE) are major health problems that lead to significant morbidity and mortality. In the United States, it is estimated that these two problems result in over 300,000 hospitalizations annually and available data indicate that 50,000 to 100,000 patients per year die of pulmonary embolism.The advent of several diagnostic tests has permitted the identification of groups of patients at high risk for development of deep venous thrombosis and subsequent pulmonary embolism. Identification of these patient groups has led to therapeutic measures designed to prevent both deep venous thrombosis and subsequent embolic episodes. However, the efficacy of these preventive measures have not been widely adopted and reservations have been expressed regarding use of low dose anticoagulant drugs for prevention of DVT and PE, especially in surgical patients. Because of the apparent reluctance to adopt putative preventive measures for DVT and PE, the National Heart, Lung and Blood Institute convened a Consensus Development Conference on the issue of prevention in 1986. Experts from North America, Europe, and South Africa presented data, both pro and con, on prevention of DVT and PE, using one or more therapeutic regimens. An impartial Panel was then asked to arrive at a consensus statement on the following questions: 1) the level of risk of DVT and PE in different patient groups; 2) the efficacy and safety of prophylactic measures in these groups; 3) the recommended prophylactic regimens for different patient groups, and 4) remaining questions related to prevention of DVT and PE. Recommendations for prevention were based on the assumption that reduction in DVT would also result in reduction of pulmonary embolism. Furthermore, the consensus was based, at least in part, upon data combined from multiple clinical trials. Thus, combined data on 12,000 individuals in randomized clinical trials indicated that in appropriate patient groups, treated with low dose heparin, there was a 68 percent reduction in DVT, as measured by the 125I-fibrinogen uptake test and venography, and that there was a reduction of 49% in pulmonary embolism and a significant decrease in overall mortality resulting from pulmonary embolism.Prophylactic measures for the following different patient groups were assessed: 1) general surgery; 2) orthopedic surgery; 3) urology; 4) gynecology-obstetrics; 4) neurosurgery and neurology; 5) trauma; and 6) medical conditions.Basically, the following prophylactic regimens were considered: 1) low dose heparin; 2) low dose dihydroergotamine heparin; 3) dextran; 4) low dose warfarin; and 5) external pneumatic compression. In general terms, low dose heparin appears to be one of the more effective prophylactic regimens in certain groups of high risk patients. This regimen is not useful in orthopedic or certain neurosurgical procedures where heparin has been shown to be of little value or hazardous. In these cases, dextran, warfarin, or external pnuematic compression may be more beneficial. In some groups of high risk patients, combination of mechanical measures with anticoagulant agents appear to be of value in prevention of DVT and PE.The recommendations of the Consensus Panel for Prevention of DVT and PE for each patient group will be assessed.

APA, Harvard, Vancouver, ISO, and other styles

8

Gillmeyer, K. R., D. R. Miller, S. T. Rinne, et al. "Outcomes of Pulmonary Vasodilator Use in a National Cohort of Veterans with Pulmonary Hypertension Associated with Left Heart Disease and Lung Disease." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2079.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Levine, P. H. "ACQUIRED IMMUNODEFICIENCY SYNDROME, HUMAN IMMUNODEFICIENCY VIRUS AND HEMOPHILIA." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644752.

Full text

Abstract:

Less than 15 years ago the National Heart, Lung and Blood Institute surveyed physicians in the United States in order to characterize the demographics of hemophilia. The average age of persons with hemophilia in the United States was found to be 11.5 years old. By 10 years later, the life expectancy was predicted to be normal, and indeed the average age of persons with hemophilia in the U.S. is now in the early twenties. Early, intensive and predictably efficacious control of hemorrhage has made this result possible, and the therapeutic product which has allowed such control is commercial clotting factor concentrate.We now know that starting in 1978, and with great frquency during 1982 and 1983, the majority of U.S. hemophiliacs were infected with human immunodeficiency virus (HIV). It is estimated that as of January, 1987, approximately two thirds of the 20,000' persons with hemophilia in the United States have been infected with HIV. Among those with severe factor VIII deficiency, more than 9056 are seropositive. As of 1/5/87, there were 288 cases of AIDS among U.S. hemophiliacs, for an AIDS rate of approximately 2.256 of those with HIV infection. This number included 185 with severe, 32 with moderate and 28 with mild hemophilia A; 12 with severe, 6 with moderate and 1 with mild hemophilia B; 9 with vWD, and 4 others. A disproportionate number were older patients: 55 were ages 1-19; 62 ages 20-29; 85 ages 30-39, and 86 age 40 or older. Although the AIDS attack rate is no longer climbing logarhythmically, new cases are certainly still occurring.A variety of other HIV-related syndromes have emerged. Of great concern is immune thrombocytopenia, which is now relatively common; among a group of 209 carefully followed HIV-positive patients at our center, 31 (1556) are or have been thrombocytopenic. Progressive failure to normally gain height and weight in children with hemophilia has recently been shown by our group to correlate with HIV antibody positivity, and also with decreased T4/T8 ratio, decreased T4 cell count, decreased skin test reactivity, and subsequent development of ARC or AIDS in some such children. Finally, a picture of progressive fall in T4 count associated with recurrent non-specific infections and increased likelihood of positive viral culture, may predict an increased risk of developing AIDS.We know that the immune dysfunction in hemophilia is complex, and not wholly explained by HIV infection. One important factor may be the many foreign proteins contained in commercial clotting factor concentrates, and their ability to stimulate T cells. It is known that latent HIV infection in cultured T4 lymphocytes can be induced to enter the proliferative, viral secretory phase by the addition of soluble foreign antigens to the cell culture. Recent data of Brettler and colleagues, to be presented at this meeting, suggest that the use of highly purified VI!I:C (specific activity >3000 u/mg) in place of the present extremely impure products, may improve the immune dysfunction in hemophilia. This observation offers a new hypothetical approach to the prevention of progressive T4 cell depletion in HIV infected hemophiliacs, and requires immediate and extensive further study.The psychosocial burden of HIV infection is immense. The need for extensive, formal education and support programs is largely unmet in most parts of the world. Such programs are best run out of hemophilia treatment centers in most cases, and must include an active program on prevention of sexual transmission, provision of HIV testing before and during pregnancies, provision for maintenance of confidentiality, etc. Education concerning HIV is like all other forms of education. It requires formal organization, a curriculum, active rather than passive learning in which there is interaction between the teacher and the pupil, time for planned repetition, reinforcement with written materials, and assessment of goals achieved. For all of these reasons it is inappropriate to assume that the physician at the hemophilia center will be able to provide an adequate education program. Adquate paramedical personnel will need to undertake this effort, under the directjon of the physician.

APA, Harvard, Vancouver, ISO, and other styles

10

Ågren, Niklas D., Mats O. Westermark, Michael A. Bartlett, and Torbjörn Lindquist. "First Experiments on an Evaporative Gas Turbine Pilot Power Plant: Water Circuit Chemistry and Humidification Evaluation." In ASME Turbo Expo 2000: Power for Land, Sea, and Air. American Society of Mechanical Engineers, 2000. http://dx.doi.org/10.1115/2000-gt-0168.

Full text

Abstract:

The evaporative gas turbine (EvGT), also known as the humid air turbine (HAT) cycle, is a novel advanced gas turbine cycle that has attracted considerable interest for the last decade. This high efficiency cycle shows the potential to be competitive with Diesel engines or combined cycles in small and intermediate scale plants for power production — and/or cogeneration. A 0.6 MW natural gas fired EvGT pilot plant has been constructed by a Swedish national research group in cooperation between universities and industry. The plant is located at the Lund Institute of Technology, Lund, Sweden. The pilot plant uses a humidification tower with metallic packing in which heated water from the flue gas economizer is brought into direct counter current contact with the pressurized air from the compressor. This gives an efficient heat recovery and thereby a thermodynamically sound cycle. As the hot sections in high temperature gas turbines are sensitive to particles and alkali compounds, water quality issues need to be carefully considered. As such, apart from evaluating the thermodynamic and part load performance characteristics of the plant, and verifying the operation of the high pressure humidifier, much attention is focused on the water chemistry issues associated with the recovery and reuse of condensate water from the flue gas. A water treatment system has been designed and integrated into the pilot plant. This paper presents the first water quality results from the plant. The experimental results show that the condensate contains low levels of alkali and calcium, around 2 mg/l Σ(K,Na,Ca), probably originating from the unfiltered compressor intake. About 14 mg/l NO2− + NO3− comes from condensate absorption of flue gas NOx. Some Cu is noted, 16 mg/l, which originates from copper corrosion of the condenser tubes. After CO2-stripping, condensate filtration and a mixed bed ion exchanger, the condensate is of suitable quality for reuse as humidification water. The need for large quantities of demineralized water has by many authors been identified as a drawback for the evaporative cycle. However, by cooling the humid flue gas, the recovery of condensed water cuts the need of water feed. A self supporting water circuit can be achieved, with no need for any net addition of water to the system. In the pilot plant, this was achieved by cooling the flue gas to around 35°C.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!